Skip to content

Released Nov 12, 2024, before the open

10-Q filed Nov 12, 2024, 43 days after period end · 0001576885-24-000098

Q3 2024 · 10-Q
Revenue—
Net Income-$29.77MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.50N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$32,265,000N/M
Operating Cash Flowderived-$24,596,000N/M
Free Cash Flowderived-$24,596,000N/M

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Net Income-$29.77M-$12.96M-$10.71M-$3.90M
EPS Diluted-$0.50-$0.24-$0.26-$0.10

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR